Phase 3 N=97 Prospective Study of Patients With Thrombocytopenia Following HSCT
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Isolated Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL — 93 percentage of participants
Phase 3 N=122 Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days — 57; 29 Participants — p=0.7186
Phase 3 N=165 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001
Phase 2 N=63 Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer · Chemotherapy-Induced Thrombocytopenia · Non-Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events — 12; 16; 18; 14 Participants
Phase 2 N=39 A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
Chemotherapy-Induced Thrombocytopenia · Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Change in Platelet Nadir — 17.1; 11.2; 5.1; -5.2 10^9/L — p=0.9654
Phase 2 N=34 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Thrombocytopenia · Neutropenia · Lymphopenia
Primary: Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3 — 20.0; 11.7; 21.5 Percentage of cycles
Phase 2 N=55 AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
Solid Tumors · Advanced Cancer
Primary: Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy — 0; 0; 1; 4 participants
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Phase 2 N=62 Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Multiple Myeloma · Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Days Post HDT-AHCT Requiring Transfusions or Grade 4 CTCAE Thrombocytopenia — 6 days
Phase 2 N=60 Eltrombopag for Post Transplant Thrombocytopenia
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Phase 2 N=8 Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Phase 3 N=102 A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Phase 1 N=19 Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
Thrombocytopenia · Acute Radiation Syndrome
Primary: Maximum Tolerated Dose (MTD) of Eltrombopag — 300 mg/day
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 2 N=122 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants
Phase 2 N=51 Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
Leukemia
Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants
Phase 3 N=64 Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Thromboembolism of Vein VTE in Colorectal Cancer · Thromboembolism of Vein in Pancreatic Cancer · Thromboembolism of Vein in Non-small Cell Lung Cancer
Primary: Percent Change in D-dimer Value — 9.9; -21.9 percent change — p=0.92
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Phase 3 N=26 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Primary: Remission Duration — 3; 11 Participants
Phase 3 N=92 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Phase 2 N=19 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Phase 3 N=26 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura
Primary: Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm — 3; 1 participants
Phase 3 N=51 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=89 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Phase 4 N=162 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants